Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

The Lancet

Volumn 384, Issue 9959, 2014, Pages 2027-2035

  Schröder, Fritz H ^a   Hugosson, Jonas ^b   Roobol, Monique J ^a   Tammela, Teuvo L J ^c,d   Zappa, Marco ^e   Nelen, Vera ^f   Kwiatkowski, Maciej ^g,h   Lujan, Marcos ^i,j,k   Määttänen, Liisa ^l   Lilja, Hans ^m,n,o,p   Denis, Louis J ^q   Recker, Franz ^g   Paez, Alvaro ^j,r,s   Bangma, Chris H ^a   Carlsson, Sigrid ^b,m   Puliti, Donella ^e   Villers, Arnauld ^t   Rebillard, Xavier ^u   Hakama, Matti ^d,l   Stenman, Ulf Hakan ^v   Kujala, Paula ^w   Taari, Kimmo ^v   Aus, Gunnar ^x   Huber, Andreas ^g   Van Der Kwast, Theo H ^a   Van Schaik, Ron H N ^a   De Koning, Harry J ^a   Moss, Sue M ^y   Auvinen, Anssi ^d   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e ISPO   (Italy)

^f Provinciaal Instituut voor Hygiene   (Belgium)

^g CANTONAL HOSPITAL AARAU   (Switzerland)

^h Academic Hospital Braunschweig   (Germany)

ⁱ HOSPITAL INFANTA CRISTINA   (Spain)

^j HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^k UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^l FINNISH CANCER REGISTRY   (Finland)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ UNIVERSITY OF OXFORD   (United Kingdom)

^o LUND UNIVERSITY   (Sweden)

^p TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^q Oncology Centre of Antwerp   (Belgium)

^r HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^s UNIVERSIDAD REY JUAN CARLOS   (Spain)

^t UNIV LILLE   (France)

^u Clinique Beausoleil   (France)

^v HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^w FIMLAB LABORATORIES   (Finland)

^x UNIVERSITY OF GOTHENBURG   (Sweden)

^y QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; GROUPS BY AGE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT RISK; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SECONDARY ANALYSIS; SELECTION BIAS; CLINICAL TRIAL; EUROPE; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS;

AGED; EUROPE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84919871373     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60525-0     Document Type: Article

References (29)

1. FH Schröder, J Hugosson, MJ Roobol the ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
2. FH Schröder, J Hugosson, MJ Roobol the ERSPC Investigators Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
3. G Draisma, R Boer, SJ Otto et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
4. MR Cooperberg, DP Lubeck, MV Meng, SS Mehta, PR Carroll The changing face of low-risk prostate cancer: trends in clinical presentation and primary management J Clin Oncol 22 2004 2141 2149
5. EAM Heijnsdijk, EM Wever, A Auvinen et al. Quality-of-life effects of prostate-specific antigen screening N Engl J Med 367 2012 595 605
6. FH Shröder, RAM Damhuis, WJ Kirkels et al. European randomized study of screening for prostate cancer - the Rotterdam pilot studies Int J Cancer 65 1996 145 151
7. FH Schröder, LJ Denis, W Kirkels, HJ de Koning, B Standaert European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies Cancer 76 1995 129 134
8. UH Stenman, M Hakama, P Knekt, A Aromaa, L Teppo, J Leinonen Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer Lancet 344 1994 1594 1598
9. PH Gann, CH Hennekens, MJ Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
10. European Randomized Study of Screening for Prostate Cancer Study protocol ERSPC. Last updated Sept 10, 1998 http://www.erspc.org/pub-pdf-pubs/studie%20boek%20voor%20website.pdf (accessed Jan 10, 2014).
11. MJ Roobol, FH Schröder European Randomized study of Screening for Prostate Cancer: achievements and presentation BJU Int 92 2003 117 122
12. HJ de Koning, MK Liem, CA Baan, R Boer, FH Schröder, FE Alexander the ERSPC Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial Int J Cancer 98 2002 268 273
13. HJ De Koning, J Blom, JW Merkelbach et al. Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int 92 2003 71 78
14. T Mäkinen, P Karhunen, J Aro, J Lahtela, L Määttänen, A Auvinen Assessment of causes of death in a prostate cancer screening trial Int J Cancer 122 2008 413 417
15. HJ De Koning, T Hakulinen, SM Moss, J Adolfsson, PH Smith, FE Alexander the ERSPC Monitoring the ERSPC trial BJU Int 92 2003 112 114
16. J Cuzick, R Edwards, N Segnan Adjusting for non-compliance and contamination in randomized clinical trials Stat Med 16 1997 1017 1029
17. OO Aalen Nonparametric inference for a family of counting processes Ann Stat 6 1978 701 727
18. DL DeMets, KK Lan Interim analysis: the alpha spending function approach Stat Med 13 1994 1341 1352
19. D Ilic Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies Recent Results Cancer Res 202 2014 65 71
20. Independent UK Panel on Breast Cancer Screening The benefits and harms of breast cancer screening: an independent review Lancet 380 2012 1778 1786
21. FH Schröder, J Hugosson, S Carlsson et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Eur Urol 62 2012 745 752
22. M Popiolek, JR Rider, O Andrén et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up Eur Urol 63 2013 428 435
23. AJ Vickers, D Ulmert, DD Sjoberg et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study BMJ 346 2013 f2023
24. T Wolters, MJ Roobol, EW Steyerberg et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC Int J Cancer 126 2010 2387 2393
25. M Zappa, D Puliti, J Hugosson et al. A different method of evaluation of the ERSPC trials confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality Eur Urol 2014 10.1016/j.eururo.2013.12.055 published online Jan 7.
26. GL Andriole, ED Crawford, RL Grubb 3rd the PLCO Project Team Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125 132
27. FH Schröder ERSPC, PLCO Studies and Critique of Cochrane Review 2013 Recent Results Cancer Res 202 2014 59 63
28. S Loeb, A Vellekoop, HU Ahmed et al. Systematic review of complications of prostate biopsy Eur Urol 64 2013 876 892
29. S Loeb, HB Carter, SI Berndt, W Ricker, EM Schaeffer Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare J Urol 189 2013 867 870